Lupin Received FDA Approval for Phytonadione Injectable
The U.S. FDA approved Lupin’s prefilled syringe version of the drug used to treat vitamin K deficiency.
Updated on Oct. 9, 2026 in Healthcare
Live Poll
Do you trust that new FDA drug approvals generally lead to better outcomes for your household?
Lupin has received U.S. FDA approval for its Phytonadione Injectable Emulsion prefilled syringe. The medication is indicated for the treatment of hypoprothrombinemia and vitamin K deficiency.
Why it matters
The approval allows Lupin to enter the U.S. market with a bioequivalent version of a drug currently marketed by International Medication Systems. The product is positioned to compete for a segment of the market that recorded $52.3 million in annual sales as of August 2026.
The Phytonadione Injectable Emulsion is approved with a dosage strength of 1 mg/0.5 mL. Market data indicates the drug generated $52.3 million in annual U.S. sales as of August 2026.
The players
Lupin
Lupin is a multinational pharmaceutical company that develops and manufactures a wide range of generic and branded formulations.
U.S. FDA
The U.S. Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of drugs and medical devices.
International Medication Systems
International Medication Systems is a pharmaceutical company that acts as the manufacturer of the reference listed drug for Phytonadione.
The details
The U.S. FDA determined that Lupin’s prefilled syringe is bioequivalent to the reference listed drug marketed by International Medication Systems. In addition to this approval, the company also recently received authorization for its Sodium Zirconium Cyclosilicate treatment, which is bioequivalent to Lokelma for Oral Suspension.
Timeline
August 10, 2026: Lupin received FDA approval for Sodium Zirconium Cyclosilicate.
August 2026: Phytonadione annual U.S. sales were estimated at $52.3 million.
October 8, 2026: Lupin shares closed the trading day at ₹1,947.
Market Landscape
The approval fits into a broader industry trend of pharmaceutical companies utilizing the Abbreviated New Drug Application pathway to capture market share from established reference drugs. This move allows Lupin to compete directly in the generic injectables sector against existing suppliers.
The introduction of a new bioequivalent version of Phytonadione may lead to increased competition and potential cost savings for healthcare providers and patients. Patients prescribed this treatment for vitamin K deficiency may see additional options available at their clinical facilities.
The takeaway
Lupin continues to expand its U.S. portfolio through the successful FDA approval of bioequivalent treatments. These product additions serve to strengthen the company's competitive position within the generic specialty drug market.
Further reading
For more on industry regulatory developments, visit the Healthcare section.
Live Poll
Do you trust that new FDA drug approvals generally lead to better outcomes for your household?
